Education
About Us
Working with TipRanks
Follow Us
TG Therapeutics (TGTX)
NASDAQ:TGTX
TGTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.93 - $43.15
Previous CloseN/A
Volume723.16K
Average Volume (3M)2.90M
Market Cap
$6.75B
Enterprise Value$3.67B
Total Cash (Recent Filing)$179.89M
Total Debt (Recent Filing)$253.72M
Price to Earnings (P/E)308.0
Beta1.84
Next Earnings
May 06, 2025EPS Estimate
0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding157,070,570
10 Day Avg. Volume3,416,546
30 Day Avg. Volume2,903,950
Financial Highlights & Ratios
PEG Ratio3.06
Price to Book (P/B)N/A
Price to Sales (P/S)25.50
Price to Cash Flow (P/CF)-138.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.54
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.64
Enterprise Value/Ebitda73.48
Forecast
1Y Price Target
$42.80Price Target Upside0.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Commercial SuccessStrong Briumvi commercial execution sets up for another beat and raise year.
Market Share GrowthRecent data disclosure indicates Briumvi market share gain trajectory has so much more room to run.
Bears Say
Competitive PressureThere are competitive headwinds expected to strengthen for Briumvi with the introduction of subq use of Kesimpta and Ocrevus.
Market Valuation ConcernsAnalyst reiterates the Underperform rating and $10 price objective based on an overvalued total market opportunity for Briumvi in the long-term.
---
Ownership Overview
9.91% Insiders
16.36% Mutual Funds
11.86% Other Institutional Investors
37.64% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TGTX FAQ
What was TG Therapeutics’s price range in the past 12 months?
TG Therapeutics lowest stock price was $12.93 and its highest was $43.15 in the past 12 months.
What is TG Therapeutics’s market cap?
TG Therapeutics’s market cap is $6.75B.
When is TG Therapeutics’s upcoming earnings report date?
TG Therapeutics’s upcoming earnings report date is May 06, 2025 which is in 42 days.
How were TG Therapeutics’s earnings last quarter?
TG Therapeutics released its earnings results on Mar 03, 2025. The company reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.157 by -$0.007.
Is TG Therapeutics overvalued?
According to Wall Street analysts TG Therapeutics’s price is currently Undervalued.
Does TG Therapeutics pay dividends?
TG Therapeutics does not currently pay dividends.
What is TG Therapeutics’s EPS estimate?
TG Therapeutics’s EPS estimate is 0.16.
How many shares outstanding does TG Therapeutics have?
TG Therapeutics has 157,070,570 shares outstanding.
What happened to TG Therapeutics’s price movement after its last earnings report?
TG Therapeutics reported an EPS of $0.15 in its last earnings report, missing expectations of $0.157. Following the earnings report the stock price went up 14.39%.
Which hedge fund is a major shareholder of TG Therapeutics?
Currently, no hedge funds are holding shares in TGTX
---
TG Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.80 (0.45% Upside)
$42.80 (0.45% Upside)
Blogger Sentiment
Bullish
TGTX Sentiment 85%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $629.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.9%
Last 30 Days ▼ 6.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
181.90%
12-Months-Change
Fundamentals
Return on Equity
12.21%
Trailing 12-Months
Asset Growth
75.28%
Trailing 12-Months
Company Description
TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
---
TGTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong performance and growth in revenue, successful product launches, and positive clinical developments. However, challenges remain with competitive market pressures and ongoing development of the subcutaneous formulation.Read More>---
TGTX Stock 12 Month Forecast
Average Price Target
$42.80
▲(0.45% Upside)
Technical Analysis
Best Analysts Covering TGTX
1 Year
1 Year Success Rate
14/15 ratings generated profit
1 Year Average Return
+86.20%
reiterated a buy rating 4 months ago
Copying Eric Joseph's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +86.20% per trade.
---